Ginsenoside Rb1 reduces fatty liver by activating AMP-activated protein kinase in obese rats

Ling Shen, Ye Xiong, David Q.‐H. Wang, Philip N. Howles, Joshua E. Basford, Jiang Wang, Yu Xiong, David Y. Hui, Stephen C. Woods, Min Liu

Journal of Lipid Research · 2013 · 126 citations · 21 references

DOIFull text

Open access

Concepts

Abstract

Ginsenoside Rb1 (Rb1), a natural compound extracted from ginseng, exerts anti-obesity activity and improves insulin sensitivity in high-fat diet (HFD)-induced obese rats. The objective of the current study was to evaluate the protective effect of Rb1 on fatty liver in HFD-induced obese rats and to elucidate underlying mechanisms. After chronic intraperitoneal administration, Rb1 (10 mg/kg) significantly ameliorated hepatic fat accumulation in HFD-induced obese rats, as demonstrated by reduced liver weight, hepatic triglyceride content, and histological evaluation of liver sections by hematoxylin and eosin and Oil Red O staining. Using primary cultured rat hepatic cells, we found that the rate of fatty acid oxidation and the activity of carnitine palmitoyltransferase 1 (CPT1), a key enzyme in fatty acid β-oxidation, were significantly elevated in Rb1-treated hepatocytes compared with those of vehicle-treated cells. HPLC analysis revealed that Rb1 increased the cellular AMP/ATP ratio, which is associated with elevated activation of hepatic AMP-activated protein kinase (AMPK) and phosphorylated acetyl-CoA carboxylase. Consistent with the activation of AMPK, Rb1 stimulated the expression of genes encoding fatty acid oxidative enzymes and proteins, and suppressed the expression of genes encoding enzymes or proteins that function in lipogenesis, assessed by quantitative PCR. We conclude that Rb1 has a potent ability to reduce hepatic fat accumulation and might be useful as a therapeutic agent for fatty liver disorder. Ginsenoside Rb1 (Rb1), a natural compound extracted from ginseng, exerts anti-obesity activity and improves insulin sensitivity in high-fat diet (HFD)-induced obese rats. The objective of the current study was to evaluate the protective effect of Rb1 on fatty liver in HFD-induced obese rats and to elucidate underlying mechanisms. After chronic intraperitoneal administration, Rb1 (10 mg/kg) significantly ameliorated hepatic fat accumulation in HFD-induced obese rats, as demonstrated by reduced liver weight, hepatic triglyceride content, and histological evaluation of liver sections by hematoxylin and eosin and Oil Red O staining. Using primary cultured rat hepatic cells, we found that the rate of fatty acid oxidation and the activity of carnitine palmitoyltransferase 1 (CPT1), a key enzyme in fatty acid β-oxidation, were significantly elevated in Rb1-treated hepatocytes compared with those of vehicle-treated cells. HPLC analysis revealed that Rb1 increased the cellular AMP/ATP ratio, which is associated with elevated activation of hepatic AMP-activated protein kinase (AMPK) and phosphorylated acetyl-CoA carboxylase. Consistent with the activation of AMPK, Rb1 stimulated the expression of genes encoding fatty acid oxidative enzymes and proteins, and suppressed the expression of genes encoding enzymes or proteins that function in lipogenesis, assessed by quantitative PCR. We conclude that Rb1 has a potent ability to reduce hepatic fat accumulation and might be useful as a therapeutic agent for fatty liver disorder. Fatty liver, the initial stage of nonalcoholic fatty liver disease (NAFLD), is a common metabolic symptom and is strongly associated with obesity and insulin resistance (1Postic C. Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.J. Clin. Invest. 2008; 118: 829-838Crossref PubMed Scopus (906) Google Scholar). Fatty liver is characterized by an increased content of hepatocellular lipids and is frequently associated with steatohepatitis and hepatocellular injury, which eventually may result in severe liver damage including bridging fibrosis and cirrhosis (2Neuschwander-Tetri B.A. Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.Hepatology. 2003; 37: 1202-1219Crossref PubMed Scopus (1790) Google Scholar). Although the molecular mechanisms underlying fatty liver are not fully understood, dysregulation of hepatic lipid homeostasis caused by pathological conditions such as reduced fatty acid oxidation, enhanced de novo lipogenesis, elevated hepatic fatty acid influx, and/or increased systemic insulin resistance are thought to be important in the development of fatty liver (3Parekh S. Anania F.A. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease.Gastroenterology. 2007; 132: 2191-2207Abstract Full Text Full Text PDF PubMed Scopus (245) Google Scholar). Indeed, therapies aimed at reducing body weight and/or alleviating insulin resistance reduce fatty liver (4Adams L.A. Angulo P. Treatment of non-alcoholic fatty liver disease.Postgrad. Med. J. 2006; 82: 315-322Crossref PubMed Scopus (212) Google Scholar). AMP-activated protein kinase (AMPK) is an intracellular fuel sensor important in the regulation of lipid metabolism (5Kahn B.B. Alquier T. Carling D. Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism.Cell Metab. 2005; 1: 15-25Abstract Full Text Full Text PDF PubMed Scopus (2321) Google Scholar). In the liver, activation of AMPK leads to increased fatty acid oxidation and simultaneously to decreased lipid synthesis (6Lin C.L. Huang H.C. Lin J.K. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells.J. Lipid Res. 2007; 48: 2334-2343Abstract Full Text Full Text PDF PubMed Scopus (166) Google Scholar). Of interest, antidiabetic drugs, including metformin and the thiazolidinediones, alleviate fatty liver in humans and rodents by regulating lipid metabolism through AMPK activation (7Zhou G. Myers R. Li Y. Chen Y. Shen X. Fenyk-Melody J. Wu M. Ventre J. Doebber T. Fujii N. et al.Role of AMP-activated protein kinase in mechanism of metformin action.J. Clin. Invest. 2001; 108: 1167-1174Crossref PubMed Scopus (4407) Google Scholar). Thus AMPK represents an attractive target for therapeutic intervention in the treatment of hepatic disorders (8Viollet B. Foretz M. Guigas B. Horman S. Dentin R. Bertrand L. Hue L. Andreelli F. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders.J. Physiol. 2006; 574: 41-53Crossref PubMed Scopus (422) Google Scholar). Ginsenoside Rb1 (Rb1), a natural compound extracted from ginseng root, has a glucose-lowering action in vitro (9Park S. Ahn I.S. Kwon D.Y. Ko B.S. Jun W.K. Ginsenosides Rb1 and Rg1 suppress triglyceride accumulation in 3T3–L1 adipocytes and enhance beta-cell insulin secretion and viability in Min6 cells via PKA-dependent pathways.Biosci. Biotechnol. Biochem. 2008; 72: 2815-2823Crossref PubMed Scopus (86) Google Scholar), and we have demonstrated that Rb1 significantly reduces body weight, improves glucose tolerance, and enhances insulin action in high-fat diet (HFD)-induced obese rats (10Xiong Y. Shen L. Liu K.J. Tso P. Xiong Y. Wang G. Woods S.C. Liu M. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats.Diabetes. 2010; 59: 2505-2512Crossref PubMed Scopus (139) Google Scholar). These findings prompted us to ask whether Rb1 could reduce hepatic fat accumulation associated with obesity; and if so, to determine the mechanisms responsible for the therapeutic effect of Rb1 on HFD-induced fatty liver. Adult male Long-Evans rats (Harlan, Indianapolis, IN) were individually housed in a temperature-controlled vivarium on a 12/12 h light/dark cycle (lights on at 0000 h, lights off at 1200 h). Diets and water were provided ad libitum except where noted. All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Cincinnati. The high-fat diet containing 20 g fat (19 g butter oil and 1 g soybean oil)/100 g diet was prepared by Research Diets (Catalog #: D03082706; New Brunswick, NJ) (11Woods S.C. Seeley R.J. Rushing P.A. D舗Alessio D. Tso P. A controlled high-fat diet induces an obese syndrome in rats.J. Nutr. 2003; 133: 1081-1087Crossref PubMed Scopus (418) Google Scholar). Rb1 purified by high-performance liquid chromatography (HPLC) was purchased from Jilin University in China (10Xiong Y. Shen L. Liu K.J. Tso P. Xiong Y. Wang G. Woods S.C. Liu M. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats.Diabetes. 2010; 59: 2505-2512Crossref PubMed Scopus (139) Google Scholar). We performed HPLC (Shimadzu Corp., Kyoto, Japan) analysis and confirmed that the Rb1 had a purity of ≥98% using an Rb1 standard obtained from LKT Laboratories (St. Paul, MN). Radiochemical [9,10-3H(N9)]palmitic acid and l-[3H]carnitine were purchased from PerkinElmer (Boston, MA). HBSS, Williams’ E medium, and HepatoZYME-SFM medium were obtained from Life Technologies (Carlsbad, CA). Collagenase II was purchased from Worthington Biochemical Co. (Lakewood, NJ). The chemicals, including dexamethasone, palmitic acid, compound C, etc., were purchased from Sigma (St. Louis, MO). The antibodies for phosphorylated AMPK, AMPK, phosphorylated acetyl-CoA carboxylase (ACC), and ACC were from Cell Signaling Technology (Beverly, MA), and antibodies for LKB1 and actin from EMD Millipore (Billerica, MA). Thirty-six rats were fed the HFD for 13 weeks. The rats became obese (average body weight 596 g), and then were divided into three groups of comparable body weight. Groups 1 and 2 received ip saline or Rb1 (10 mg/kg/day), respectively, and continued to have free access to the same HFD. Because Rb1-treated rats had reduced a HFD was as a rats were the HFD with an to the of the Rb1-treated rats (10Xiong Y. Shen L. Liu K.J. Tso P. Xiong Y. Wang G. Woods S.C. Liu M. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats.Diabetes. 2010; 59: 2505-2512Crossref PubMed Scopus (139) Google Scholar). weight and were the of the the rats were h and of liver were and at or in in for as 1 g of liver was and lipids were extracted with a as by J. M. A for the and of from animal Full Text PDF PubMed Google Scholar). The of triglyceride in liver was using a (10Xiong Y. Shen L. Liu K.J. Tso P. Xiong Y. Wang G. Woods S.C. Liu M. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats.Diabetes. 2010; 59: 2505-2512Crossref PubMed Scopus (139) Google Scholar). in were with for histological sections were with a and on were then with hematoxylin and eosin and and at The of liver steatosis was by a was of the treatment that the had was on a of where was 1 was 2 was and was of hepatocytes B.A. Nonalcoholic steatohepatitis: a for and the histological J. PubMed Scopus Google Scholar). is by the on nonalcoholic fatty liver disease.Gastroenterology. Full Text Full Text PDF PubMed Scopus Google Scholar). In sections were from liver using a and with Oil Red O for the fat hepatic fatty acid oxidation and steatosis in Long-Evans Fatty J. Physiol. Physiol. 2008; PubMed Scopus Google Scholar). hepatocytes were cultured as L. Wang Liu M. and primary of rat hepatic cells.J. Scholar). rats for h were and the liver was The were with HBSS, and was by containing II After the liver was in a with a through a and three in Williams’ E The cells were then as cells in and cultured at in a the medium was with a medium for the of and the cells were cultured for an The of fatty acid oxidation in hepatocytes was as analysis of fatty acid oxidation disorders.J. Clin. Invest. PubMed Scopus Google Scholar). cultured for h were with The was in with containing Rb1 (10 and compound (7Zhou G. Myers R. Li Y. Chen Y. Shen X. Fenyk-Melody J. Wu M. Ventre J. Doebber T. Fujii N. et al.Role of AMP-activated protein kinase in mechanism of metformin action.J. Clin. Invest. 2001; 108: 1167-1174Crossref PubMed Scopus (4407) Google Scholar), or compound Rb1 (10 and which was prepared of the a of containing and the was in containing fatty The compound was into the medium to Rb1 After h the medium was to and of and 1 of 2 were After the were at g for and the containing was to a new with the and and and was by CA). palmitoyltransferase 1 activity of hepatocytes was as by et J. J. regulation of carnitine palmitoyltransferase in cultured rat and by fatty PubMed Scopus Google with were cultured for h and then with Rb1 (10 and compound or compound Rb1 (10 for an The compound was into medium to the Rb1 the cells were with and the medium was with of medium of 1 2 1 1 1 fatty 1 of and of After the cells were for the was by the of of The was at g for and the was with of 2 acid, in of and extracted with of and the in of was by liquid was extracted from the cultured primary rat hepatic cells or rat liver with an and with synthesis L. Wang Tso P. Woods S.C. Liu M. the effect of 2010; PubMed Scopus Google Scholar). The was to the NJ). was performed in a with an using as (10Xiong Y. Shen L. Liu K.J. Tso P. Xiong Y. Wang G. Woods S.C. Liu M. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats.Diabetes. 2010; 59: 2505-2512Crossref PubMed Scopus (139) Google Scholar). conditions were as for for cycle by of for and for were revealed in cycle for of the were then and the were and using the (10Xiong Y. Shen L. Liu K.J. Tso P. Xiong Y. Wang G. Woods S.C. Liu M. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats.Diabetes. 2010; 59: 2505-2512Crossref PubMed Scopus (139) Google L. Tso P. Woods S.C. Liu M. is by 2007; PubMed Scopus Google Scholar). from were as to the The of the for rat protein fatty acid carnitine palmitoyltransferase 1 and are in for genes associated with hepatic fatty acid synthesis and metabolism in to to in a new proteins were extracted from the cultured primary hepatic cells or from the of the rats using the L. Tso P. Woods S.C. Liu M. is by 2007; PubMed Scopus Google Scholar). of the proteins were by Life and then to MA). After in were with an or ACC antibodies at with After with the were with CA). The of was using an enhanced The were to were then and with or antibodies to of protein in A was for the of LKB1 and actin where the was at and was at as was as The of protein was to the protein of AMPK and respectively, and was as a protein was as for LKB1 to protein After treatment with or Rb1 for h, the cultured hepatocytes from of a were with into a and at was on in acid and to of a 1 cells were were then with on for and then to the After the to were and HPLC analysis was performed h of and were by HPLC as by A and of and in of by liquid Biotechnol. 2006; using a II Corp., at to an 1200 and was at at to at 2 at at and A at was at and were by to purchased from the conditions we the of were from with at All are as standard In vitro were in and performed on three to groups were using by for or by for of groups as a was for of effects Rb1 and were In Rb1 treatment (10 for significantly reduced g g), body weight g g), and glucose and glucose in HFD-induced obese rats, compared with treatment (10Xiong Y. Shen L. Liu K.J. Tso P. Xiong Y. Wang G. Woods S.C. Liu M. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats.Diabetes. 2010; 59: 2505-2512Crossref PubMed Scopus (139) Google Scholar). In the we whether Rb1 treatment could fatty liver in obese in liver was in Rb1-treated obese rats The of liver weight to body weight and the hepatic content in Rb1-treated obese rats was significantly reduced compared with saline reduced liver weight and hepatic content, was found for rats and saline as by Although was rats and Rb1-treated rats, the in liver weight and hepatic content Rb1-treated and rats that Rb1 has effects on lipid metabolism in the liver, which us to the steatosis and were in obese rats The from Rb1-treated obese rats had a in the of steatosis and was in rats The histological are in of such as or was in or obese rats. Using Oil Red O for the the of and rats was were and lipid in Rb1-treated compared with lipid in rats Rb1 reduced the of steatosis and lipids to a that effects on the of fatty liver in HFD-induced obese are that of the steatosis in HFD-induced obese rats with by in a new by of the mechanisms by which Rb1 reduces fatty liver is to enhance the oxidation of fatty the liver, hepatic fat Consistent with the of by Rb1-treated hepatocytes was significantly that by and effect was significantly by with compound C, an of AMPK determine whether the oxidation in Rb1-treated hepatocytes is to reduced of activity was in activity was in Rb1-treated hepatocytes compared with cells, and with compound effect We that of cellular lipid accumulation in the liver could result from suppressed expression of genes encoding enzymes or proteins that function in and/or increased expression of genes encoding fatty acid oxidative enzymes and Consistent with we found that the of the and of the key enzymes and not were significantly reduced in Rb1-treated hepatocytes compared with those in cells In Rb1 significantly increased the expression of genes encoding proteins with in fatty acid oxidation, including and not in the cultured compared with that in These were confirmed in the liver from or rats determine if the effects of Rb1 on the expression the activation of AMPK, compound C, an of the AMPK was into the medium of Rb1 significantly effects on the expression of key including and the that Rb1 in the liver the activation of the AMPK we AMPK activity in cultured primary hepatocytes and in obese rats. Rb1 increased of hepatic AMPK in and in cultured the of AMPK protein was not significantly The for at a of to AMPK is h and the is in the cultured These in the activation of AMPK were confirmed in Rb1-treated HFD-induced obese rats, compared with saline Because is that AMPK activation fatty acid oxidation by ACC (5Kahn B.B. Alquier T. Carling D. Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism.Cell Metab. 2005; 1: 15-25Abstract Full Text Full Text PDF PubMed Scopus (2321) Google Scholar), we whether Rb1 induces ACC in the cultured hepatic cells. Consistent with the increased AMPK Rb1 elevated the of phosphorylated which is the of enzyme increased the of AMPK and with (7Zhou G. Myers R. Li Y. Chen Y. Shen X. Fenyk-Melody J. Wu M. Ventre J. Doebber T. Fujii N. et al.Role of AMP-activated protein kinase in mechanism of metformin action.J. Clin. Invest. 2001; 108: 1167-1174Crossref PubMed Scopus (4407) Google Scholar). has that LKB1 as a and activating AMPK D. T. M. Carling D. LKB1 is the kinase in the AMP-activated protein kinase 2003; Full Text Full Text PDF PubMed Scopus Google Scholar), we LKB1 protein expression in or cells. Although Rb1 treatment elevated LKB1 expression to the not The activity of AMPK is by the AMP/ATP M. R. T. D. the of for and of AMP-activated protein 2006; Full Text Full Text PDF PubMed Scopus Google Scholar). determine whether Rb1 cellular content in cells, and were in cultured hepatocytes Rb1 (10 or treatment for We found that was the same was significantly increased by the of to was elevated by These that the increased of to in cultured hepatocytes may the activation of In the liver a in the metabolism of fatty Using a HFD-induced obese rat we demonstrated that of HFD to rats hepatic cellular fat accumulation and steatosis (10Xiong Y. Shen L. Liu K.J. Tso P. Xiong Y. Wang G. Woods S.C. Liu M. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats.Diabetes. 2010; 59: 2505-2512Crossref PubMed Scopus (139) Google Scholar). ip for significantly reduced the lipid accumulation and hepatic steatosis in animal and was associated with the activation of AMPK by Rb1 in the liver. Consistent with Rb1 ACC activation by and enhanced activity of to an increased rate of fatty acid Rb1 stimulated fatty acid oxidative expression and suppressed the expression of genes encoding enzymes or proteins that function in are the to that Rb1 might as a therapeutic agent to hepatic steatosis by the hepatic AMPK The Long-Evans rat has for of obesity and of to fed a high-fat diet (11Woods S.C. Seeley R.J. Rushing P.A. D舗Alessio D. Tso P. A controlled high-fat diet induces an obese syndrome in rats.J. Nutr. 2003; 133: 1081-1087Crossref PubMed Scopus (418) Google Scholar). In the we demonstrated that rats fatty liver chronic HFD The rats on a HFD had significantly increased hepatic content, which was confirmed by Oil Red O staining. The of liver sections with and E revealed that the obese rats had steatosis and lipid The fatty liver in those obese was ameliorated by chronic treatment with Rb1 significantly reduced the of liver weight to body weight as as the hepatic A in the of steatosis and lipids was in the from Rb1-treated obese rats fatty liver, the in of liver weight, hepatic content, and the of steatosis and the saline and was not as as the saline and Rb1 groups that effects on the of fatty liver in HFD-induced obese are the energy Lipid accumulation in liver may be caused by reduced lipid and/or enhanced de novo We assessed whether Rb1 reduces fatty liver by fatty acid oxidation in the liver, and found that the of in Rb1-treated hepatocytes was significantly that in cells. that the oxidation by Rb1 is to reduced of we the activity of and found that was in Rb1-treated hepatocytes compared with in cells AMPK is a key sensor of cellular energy and has in the of hepatic lipid homeostasis (5Kahn B.B. Alquier T. Carling D. Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism.Cell Metab. 2005; 1: 15-25Abstract Full Text Full Text PDF PubMed Scopus (2321) Google Scholar). AMPK of a containing a and and The a which could be phosphorylated by such as the kinase LKB1 D. T. M. Carling D. LKB1 is the kinase in the AMP-activated protein kinase 2003; Full Text Full Text PDF PubMed Scopus Google Scholar). Activation of AMPK by at leads to the and regulation of a of in lipid metabolism P. lipid metabolism and non-alcoholic fatty liver Metab. Full Text Full Text PDF PubMed Scopus Google Scholar). ACC has ACC is the enzyme in the synthesis of which is not a for the of fatty a potent of fatty acid oxidation through action on a of fatty groups into the to of acetyl-CoA PubMed Scopus Google Scholar). The is that AMPK to a in content, as as a in fatty acid and oxidation in the We that of fatty liver from increased hepatic AMPK we the of AMPK in Rb1-treated obese rats. with fat accumulation in the liver, chronic treatment with Rb1 significantly enhanced AMPK activation that the hepatic AMPK an important in in was by in vitro using primary cultured rat in which Rb1 treatment to increased of AMPK and ACC in and AMPK is a protein and the activity of AMPK is by activating including the a kinase D. T. M. Carling D. LKB1 is the kinase in the AMP-activated protein kinase 2003; Full Text Full Text PDF PubMed Scopus Google Scholar), and by the AMP/ATP M. R. T. D. the of for and of AMP-activated protein 2006; Full Text Full Text PDF PubMed Scopus Google Scholar). determine the mechanisms effect on AMPK, cultured hepatocytes were with Rb1 (10 or for LKB1 protein expression was by and and were by HPLC LKB1 expression was not significantly increased in Rb1-treated cells compared with cells. we found that Rb1 significantly increased the compared with were to in the of to These that the increased of to by Rb1 in cultured hepatocytes may activation of a of energy AMPK has found to metabolic that energy and energy by the of the key such as and (7Zhou G. Myers R. Li Y. Chen Y. Shen X. Fenyk-Melody J. Wu M. Ventre J. Doebber T. Fujii N. et al.Role of AMP-activated protein kinase in mechanism of metformin action.J. Clin. Invest. 2001; 108: 1167-1174Crossref PubMed Scopus (4407) Google Scholar). is as the regulating the expression of genes encoding enzymes or proteins that function in in the liver including a key enzyme in de novo fatty acid synthesis in as a for regulation of enzymes in the Med. PubMed Scopus Google Scholar), and a enzyme in the of fatty which are for the of in the liver The regulation of Lipid Res. PubMed Scopus Google Scholar). In the of and were significantly by Rb1 that of lipid accumulation is associated with decreased expression of and fatty acid oxidation has to be a mechanism underlying in lipid accumulation in liver. is a in the regulation of and fatty acid oxidation of energy metabolism in and Clin. Invest. 2006; PubMed Scopus Google Scholar). was as a for has found to as a of and is in the of the genes encoding enzymes of fatty acid oxidation The with in of genes encoding fatty acid oxidation PubMed Scopus Google Scholar). which is in the liver, activation of fatty T. J. of the of the in in of the effects of PubMed Scopus Google and S. T. C. T. C. Fujii T. S. Y. et from acid, and hepatic triglyceride in obese PubMed Scopus Google M. G. M. S. analysis of regulation by the and PubMed Scopus Google Scholar). In the current Rb1 significantly increased the activity of and expression of and with fatty acid in and of hepatic cells. All of the in expression in cultured hepatocytes Rb1 were confirmed in liver from or vehicle-treated obese rats the effects of Rb1 on the expression of key including and were significantly by compound C, an of AMPK that such effects of Rb1 the activation of AMPK In that Rb1 significantly reduces cellular lipid accumulation in the liver of HFD-induced obese in effect is by the AMP/ATP ratio, to the activation of the AMPK Consistent with Rb1 treatment increased the rate of fatty acid oxidation, stimulated the expression of fatty acid oxidative and suppressed the expression of genes encoding enzymes or proteins that function in These new understanding as to Rb1 lipid and for evaluation of the therapeutic of Rb1 in The for acetyl-CoA carboxylase 1 AMP-activated protein kinase carnitine palmitoyltransferase fatty acid hematoxylin and eosin high-fat diet nonalcoholic fatty liver disease quantitative ginsenoside Rb1 protein triglyceride

References

21